Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index

Aims : Counting mitotic figures is considered to be a reliable prognosticator, but evaluation of Ki67 immunohistochemistry has become more popular in evaluating proliferation. Our previous studies suggested an occasional discrepancy between mitotic figures and Ki67 fraction. The aim of this study was to investigate this more closely and also to study the associations between bcl‐2 and p53 expression and proliferation.

[1]  H. Joensuu,et al.  Bcl-2 protein expression and long-term survival in breast cancer. , 1994, The American journal of pathology.

[2]  P. Porter,et al.  Hormonal Factors and Breast Tumor Proliferation: Do Factors that Affect Cancer Risk also Affect Tumor Growth? , 2004, Breast Cancer Research and Treatment.

[3]  P. Kronqvist,et al.  Bcl-2 immunostaining: a way to finding unresponsive postmenopausal N+ breast cancer patients. , 2000, Anticancer research.

[4]  J. Schulte‐Mönting,et al.  Ki‐67 immunostaining in human breast tumors and its relationship to prognosis , 1991, Cancer.

[5]  V. Kosma,et al.  The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[6]  J. Baak,et al.  The value of morphometry to classic prognosticators in breast cancer , 1985, Cancer.

[7]  T. Kuopio,et al.  Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. , 2005, Anticancer research.

[8]  G. Licata,et al.  Obesity and cardiovascular risk: the new public health problem of worldwide proportions , 2004, Expert review of cardiovascular therapy.

[9]  R. Camplejohn,et al.  Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. , 1988, British Journal of Cancer.

[10]  P. Kronqvist,et al.  Morphometric grading in breast cancer: thresholds for mitotic counts. , 1998, Human pathology.

[11]  N. Lemoine,et al.  Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables , 1987, The Journal of pathology.

[12]  F. B. Sørensen,et al.  The prognostic relevance of estimates of proliferative activity in early breast cancer , 2003, Histopathology.

[13]  R. Gelber,et al.  Ki‐67 expression in breast carcinoma , 2003, Cancer.

[14]  R. Cote,et al.  Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques , 1994, Human pathology.

[15]  O. Kallioniemi,et al.  Evaluation of cell proliferation in breast carcinoma. Comparison of Ki‐67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count , 1990, Cancer.

[16]  A. Thor,et al.  Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Tan,et al.  Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death , 2005, Modern Pathology.

[18]  N. Keim,et al.  America's obesity epidemic: measuring physical activity to promote an active lifestyle. , 2004, Journal of the American Dietetic Association.

[19]  A. Marchetti,et al.  p53 Mutations and Histologie Type of Invasive Breast Carcinoma , 1993, Cancer research.

[20]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.

[21]  Y. Collan,et al.  Volume corrected mitotic index (M/V-INDEX). The standard of mitotic activity in neoplasms. , 1989, Pathology, research and practice.

[22]  G. Pelosi,et al.  Ki‐67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosis , 1997, International journal of cancer.

[23]  Hiroko Yamashita,et al.  Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer , 2003, Breast Cancer Research.

[24]  P Kronqvist,et al.  Cysteine proteinase inhibitor cystatin A in breast cancer. , 1998, Cancer research.

[25]  R. Camplejohn,et al.  P53, apoptosis, and breast cancer , 1996, Journal of Mammary Gland Biology and Neoplasia.

[26]  F. Spyratos,et al.  Correlation between MIB‐1 and other proliferation markers , 2002, Cancer.

[27]  T. Delozier,et al.  Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma , 2003, Cancer.

[28]  P. Kronqvist,et al.  Morphometric grading in breast cancer: Tfor mitotic counts , 1998 .

[29]  P. V. van Diest,et al.  Standardized mitotic counts in breast cancer. Evaluation of the method. , 1996, Pathology, research and practice.

[30]  T. Aas,et al.  Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. , 1997, British Journal of Cancer.